Naylor ML, Yun J, Arnold D. No evidence of disease activity achievement over 4 years of peginterferon beta-1a treatment in newly diagnosed patients with relapsing Multiple Sclerosis: subgroup analyses of ADVANCE/ATTAIN. EAN 2018, poster EPR2116.
Ublituximab bij MS: 5-jaarsdata uit de open-label extensiestudie van ULTIMATE I en II
mei 2026 | Multipele Sclerose